Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 3Phase 3 1Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 9INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2CNS 1

Conditions

Prostatic Neoplasms 2Glioma 1Glioblastoma 1Astrocytoma 1Adenocarcinoma 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Valacyclovir × Clear all
NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT02768363 2025-07-30

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

Candel Therapeutics, Inc.

Phase 2 Active not recruiting
187 enrolled
Genitourinary

Prostatic Neoplasms

NCT00589875 2024-04-03

BrTK02

Candel Therapeutics, Inc.

Phase 2 Completed
52 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡